Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: A proof-of-principle trial

The Lancet Oncology

Volumn 16, Issue 7, 2015, Pages 795-803

  Golden, Encouse B ^a   Chhabra, Arpit ^b   Chachoua, Abraham ^a   Adams, Sylvia ^a   Donach, Martin ^a   Fenton Kerimian, Maria ^a   Friedman, Kent ^a   Ponzo, Fabio ^a   Babb, James S ^a   Goldberg, Judith ^a   Demaria, Sandra ^a   Formenti, Silvia C ^c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; DOCETAXEL; DOXORUBICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PACLITAXEL;

ABSCOPAL RESPONSE; ADULT; AGED; ARTICLE; BREAST CANCER; BRONCHOSPASM; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DERMATITIS; DIARRHEA; FAINTNESS; FATIGUE; FEMALE; HEMATOLOGIC DISEASE; HUMAN; IMMUNOGENICITY; LEUKOPENIA; LUNG EMBOLISM; LYMPHOCYTOPENIA; MALE; METASTATIC SOLID TUMOR; MIDDLE AGED; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVARY CANCER; PRIORITY JOURNAL; PRURITUS; SAFETY; SMALL CELL LUNG CANCER; SOLID TUMOR; THROMBOCYTOPENIA; THYMUS CANCER; TUMOR REGRESSION; UROGENITAL TRACT TUMOR; UTERINE CERVIX CANCER; VOMITING; ADJUVANT THERAPY; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; FOLLOW UP; KAPLAN MEIER METHOD; METASTASIS; MORTALITY; MULTIMODALITY CANCER THERAPY; NEOPLASMS; NONPARAMETRIC TEST; PATHOLOGY; PATIENT SELECTION; RADIATION DOSE FRACTIONATION; RADIATION RESPONSE; RISK ASSESSMENT; SURVIVAL; TREATMENT OUTCOME; UNITED STATES; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; AGED; COMBINED MODALITY THERAPY; CONFIDENCE INTERVALS; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; NEW YORK CITY; PATIENT SELECTION; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84937525789     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00054-6     Document Type: Article

References (33)

1. Mole RH Whole body irradiation; radiobiology or medicine?. Br J Radiol 1953, 26:234-241.
2. Demaria S, Ng B, Devitt ML, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 2004, 58:862-870.
3. Demaria S, Kawashima N, Yang AM, et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 2005, 11:728-734.
4. Steinman RM, Banchereau J Taking dendritic cells into medicine. Nature 2007, 449:419-426.
5. Blom B, Ho S, Antonenko S, Liu YJ Generation of interferon alpha-producing predendritic cell (Pre-DC)2 from human CD34(+) hematopoietic stem cells. J Exp Med 2000, 192:1785-1796.
6. Inaba K, Inaba M, Romani N, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992, 176:1693-1702.
7. Kroemer G, Galluzzi L, Kepp O, Zitvogel L Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013, 31:51-72.
8. Ruocco MG, Pilones KA, Kawashima N, et al. Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects. J Clin Invest 2012, 122:3718-3730.
9. Golden EB, Frances D, Pellicciotta I, Demaria S, Helen Barcellos-Hoff M, Formenti SC Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. OncoImmunology 2014, 3:e28518.
10. Twyman-Saint Victor C, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 2015, 520:373-377.
11. Golden EB, Apetoh L Radiotherapy and immunogenic cell death. Semin Radiat Oncol 2015, 25:11-17.
12. Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012, 366:925-931.
13. Golden EB, Demaria S, Schiff PB, Chachoua A, Formenti SC An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res 2013, 1:365-372.
14. Borrello I, Pardoll D GM-CSF-based cellular vaccines: a review of the clinical experience. Cytokine Growth Factor Rev 2002, 13:185-193.
15. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993, 90:3539-3543.
16. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363:411-422. the IMPACT Study Investigators.
17. Vacchelli E, Vitale I, Eggermont A, et al. Trial watch: dendritic cell-based interventions for cancer therapy. OncoImmunology 2013, 2:e25771.
18. Brody JD, Ai WZ, Czerwinski DK, et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol 2010, 28:4324-4332.
19. Grimaldi AM, Simeone E, Giannarelli D, et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. OncoImmunology 2014, 3:e28780.
20. Bramhall RJ, Mahady K, Peach AH Spontaneous regression of metastatic melanoma-clinical evidence of the abscopal effect. Eur J Surg Oncol 2014, 40:34-41.
21. Crittenden M, Kohrt H, Levy R, et al. Current clinical trials testing combinations of immunotherapy and radiation. Semin Radiat Oncol 2015, 25:54-64.
22. Anguille S, Smits EL, Lion E, van Tendeloo VF, Berneman ZN Clinical use of dendritic cells for cancer therapy. Lancet Oncol 2014, 15:e257-e267.
23. Ma Y, Kepp O, Ghiringhelli F, et al. Chemotherapy and radiotherapy: cryptic anticancer vaccines. Semin Immunol 2010, 22:113-124.
24. Formenti SC, Demaria S Systemic effects of local radiotherapy. Lancet Oncol 2009, 10:718-726.
25. Formenti SC, Demaria S Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst 2013, 105:256-265.
26. Golden EB, Formenti SC Radiation therapy and immunotherapy: growing pains. Int J Radiat Oncol Biol Phys 2015, 91:252-254.
27. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009, 15:7412-7420.
28. Dovedi SJ, Melis MH, Wilkinson RW, et al. Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma. Blood 2013, 121:251-259.
29. Dewan MZ, Vanpouille-Box C, Kawashima N, et al. Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer. Clin Cancer Res 2012, 18:6668-6678.
30. Formenti SC Is classical stereotactic radiotherapy the optimal partner for immunotherapy?. Oncology (Williston Park) 2015, 29(5).
31. Templeton AJ, McNamara MG, Šeruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 2014, 106:dju124.
32. Dovedi SJ, Adlard AL, Lipowska-Bhalla G, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res 2014, 74:5458-5468.
33. Hodi FS, Lee S, McDermott DF, et al. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA 2014, 312:1744-1753.